Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
A Registry of Subjects With Primary Indeterminate Lesions or Choroidal Melanoma
NCT03941379 · View on ClinicalTrials.gov ↗
Study Summary
The purpose of this observational research study is to follow participants who have been treated with either bel-sar or received alternate treatment (sham, standard of care therapy, etc.) while participating in a previous Aura Biosciences clinical research study to assess the long-term safety and effectiveness in these subjects. This study will collect information from procedures conducted as part of routine follow-up eye care and cancer care. Additionally, the registry will collect all adverse events, information about pregnancy and symptomatic overdose.
Conditions Studied
Study Locations (16)
California
- UCLA Jules Stein Eye Institute — Los Angeles
- Byers Eye Institute at Stanford University — Palo Alto
- Retina Consultants of Sacramento — Sacramento
Michigan
- W. K. Kellogg Eye Center, University of Michigan — Ann Arbor
- Associated Retinal Consultants, PC — Royal Oak
Texas
- Texas Retina Associates — Dallas
- Retina Consultants of Houston — Houston
Arizona
- Retina Associates SW, P.C. — Tucson
Massachusetts
- Massachusetts Eye and Ear Infirmary — Boston
Minnesota
- Retina Center — Minneapolis
New York
- Columbia University Medical Center — New York
Oregon
- Oregon Health & Science University Casey Eye Institute — Portland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 500 participants |
| Start Date | 2019-03-27 |
| Est. Completion | 2029-12 |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03941379
The ClinicalTrials.gov registry entry for NCT03941379 describes a study currently listed as recruiting. It is categorized as an unspecified phase, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 500 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Aura Biosciences, which has 35 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 2 conditions, with Choroidal Melanoma appearing as the primary indexed condition, and to 0 interventions. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT03941379 reports 16 study locations spanning 12 distinct geographic areas — top geographies include California, Michigan, Texas. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT03941379 about?
NCT03941379 is a clinical study titled "A Registry of Subjects With Primary Indeterminate Lesions or Choroidal Melanoma". The purpose of this observational research study is to follow participants who have been treated with either bel-sar or received alternate treatment (sham, standard of care therapy, etc.) while participating in a previous Aura Biosciences clinical research study to assess the long-term safety and ef...
What is the current status of trial NCT03941379?
This trial is currently recruiting. The enrollment target is 500 participants. The study started on 2019-03-27. Estimated completion is 2029-12.
What conditions does trial NCT03941379 study?
This clinical trial studies the following conditions: Choroidal Melanoma, Indeterminate Lesions of Eye. These conditions were identified from the trial registry and reflect the primary focus areas of the research.
Who is sponsoring clinical trial NCT03941379?
This trial is sponsored by Aura Biosciences, which has 35 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT03941379 being conducted?
This trial has 16 study locations across Arizona, California, Massachusetts, Michigan, Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.